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Measure-Dependent Variation in Burden of Disease Estimates
Implications for Policy
MARTHE R. GOLD, MD, MPH,* AND PETER MUENNIG, MD, MPH†
BACKGROUND. Health adjusted life years
(HALYs) are used for estimating burden of
disease and as outcomes in cost-effectiveness
analyses of medical care and public health
interventions.
OBJECTIVES. The impact of use of health-
related quality of life (HRQL) scores associ-
ated with the disability-adjusted life year
(DALY), the quality-adjusted life year (QALY),
and the years of healthy life (YHL) measure on
burden of disease estimates by income and
race for five illnesses was studied.
RESEARCH DESIGN. Abridged life tables were
constructed using 1997 death certificate data
from the National Center for Health Statistics.
These tables were then quality-adjusted using
prevalence data from the National Health In-
terview Survey and HRQL scores obtained
using the Quality of Well-Being scale, the
DALY, and the YHL measure to estimate bur-
den of disease for five common diseases. Sep-
arate estimates were made for low and higher
income families as well as black persons and
white persons.
RESULTS. Measure-related burden of disease
estimates differed substantially from one an-
other. Rank order of disease burden was not
maintained across measures. Discrepancies in
the rank order of disease were greater when
different sociodemographic groups were
examined.
CONCLUSIONS. Diseases and demographic
groups will receive differing priorities for in-
tervention or research depending on which
measurement system is used to inform
decision-making. Refinement and standard-
ization of measures is necessary to enhance
their utility for medical care and public health
policy applications.
Key words: Burden of disease; cost-
effectiveness analysis; health-related quality
of life; resource allocation. (Med Care 2002;40:
260–266)
Increasingly, cost-effectiveness and burden of
disease studies are relying on outcome measures
that merge estimates of life expectancy with mea-
sures of the quality of life with a disease. The
morbidity or quality of life component of such
studies is referred to as “health-related quality of
life”(HRQL), and is captured on a scale of 0 to 1.0
where 0 is equivalent to death, and 1.0 represents
perfect health. These scores permit assessments of
burden of disease and cost-effectiveness for both
fatal and nonfatal conditions. For example, they
allow comparisons of conditions as varied as can-
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cer, heart disease, homicide and unintended
injury.
When HRQL is incorporated with life years,
burden of disease is measured in health-adjusted
life years (HALYs). One HALY is equal to 1 year of
life lived in perfect health.1–3 The HALY is an
umbrella term that includes quality-adjusted life
years (QALYs),2 which were developed to evaluate
economic outcomes from medical interventions,
disability-adjusted life years (DALYs),3 which were
designed to measure global burden of disease, and
years of healthy life (YHLs),4 which were designed
to monitor the health of Americans for Healthy
People 2000.5,6 Each of these summary measures of
population health has been used in estimations of
burden of disease7–9 as well as in cost-
effectiveness analyses.3,10–14
Measures that include HRQL are increasingly
used for policy development both domestically
and internationally. For example, in the United
States, clinical trials supported by the National
Institutes of Health and the Agency for Health
care Research and Quality, often use QALYs for
assessing treatment outcomes and calculating
cost-effectiveness of clinical interventions.15 Initi-
atives conducted and funded by the Centers for
Disease Control and Prevention use a variety of
approaches including QALYs and DALYs.16,17 The
Department of Health and Human Services’
(DHHS) recently released Healthy People 2010 has
as dual primary goals increasing quality and years
of healthy life and eliminating health disparities
among different segments of the population. A
tracking strategy for HALYS has not yet been
selected by DHHS. The World Health Organiza-
tion uses DALYs (among other measures) to com-
pare burden of disease across nations.3
A lack of standardization in methodological
approach by influential organizations and agen-
cies can diminish the utility of burden of disease
measurement. In considerations of resource priori-
tization—for medical care services, public health
programs or research investment—decision mak-
ers must, at minimum, have confidence that esti-
mates represent a valid ordinal ranking of diseases
and conditions for the populations they are con-
cerned with. Although DALYs, QALYs, and YHLs
share a common requirement for estimates of
disease prevalence, years of life lost caused by
disease, and condition-associated HRQL, each is
calculated using different methods.19 The differ-
ences in measure-specific approach are particu-
larly varied in the conceptualization and valuation
of HRQL. These differences may lead to discrep-
ancies in the way diseases or conditions are
prioritized.
To explore the question of how the HRQL
scores associated with each of these measures
might affect estimates of disease burden, we cal-
culate the burden of disease for five conditions. In
our models, we vary only the HRQL scores, using
QALY, DALY and YHL-associated HRQL scores
for diabetes mellitus, chronic obstructive pulmo-
nary disease, stroke, asthma and peptic ulcer dis-
ease. We assess the level of disparity in the differ-
ent estimations both between measures, and after
adjusting for race and income and explore the
implications for policy.
Materials and Methods
Using race-specific and income-specific
abridged life table cohorts,20 we estimated health-
adjusted life-years (HALYs) lost to diabetes melli-
tus, chronic obstructive pulmonary disease, stroke,
asthma, and peptic ulcer disease. We then calcu-
lated the burden of disease in HALYs by incorpo-
rating the HRQL scores (Table 1) associated with
the disability-adjusted life-year (DALY), the
Health and Activity Limitation Index (HALex)
associated with the years of healthy life (YHL)
measure, and the quality of well-being (QWB)
scale, an HRQL measure designed for the con-
struction of QALYs, into these abridged life ta-
bles.3,4,21–23 All calculations were conducted using
Excel 98 for the Macintosh (Microsoft, Redmond,
WA).
A separate abridged HRQL-adjusted life table
was constructed for each demographically defined
cohort (three measure-specific life tables for each
of the five diseases) using data from the National
Center for Health Statistics (NCHS).3,4,21–23 The
methods we used are described in detail else-
where24 and are summarized below.
In a life table, a hypothetical cohort of 100,000
persons is born each year. All persons are sub-
jected to the age appropriate risk for death or
illness, but there is no migration into or out of the
population. To determine the burden of disease in
a life table cohort, the person-years in each age
interval are multiplied by the HRQL score and
summed across age intervals.
Disease prevalence ratios were obtained from
National Health Interview Survey data and mor-
tality rates were obtained from death certificate
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data.25,26 Disease-specific mortality rates by in-
come were not available. We therefore applied
all-cause mortality data from Lantz et al27 to
develop disease-specific mortality estimates by
income.
The burden of disease was calculated for the US
population, families earning less than $10,000,
families earning more than $35,000, black persons,
and white persons. The age, income, and racial
characteristics used in our study were necessary
caused by sample size and categorical constraints
specific to the National Health Interview Survey,
which was used to generate prevalence ratios for
the life table cohorts. We chose these categories to
ensure that all model inputs would be consistent
across each of the life tables we generated.
We validated the model by comparing our esti-
mate of health-adjusted life expectancy at birth to
a 1990 estimate obtained by Erickson et al.4 Our
estimate of health-adjusted life expectancy dif-
fered from their estimate by 0.5 years, approxi-
mately reflecting fluctuations in life expectancy
and HRQL between 1990 and 1997.18
Results
The burden of disease caused by chronic ob-
structive pulmonary disease (COPD) calculated
using the HRQL score associated with the Quality
of Well-Being scale predicts that a random sample
of a United States cohort of 100,000 persons
suffered a loss of 169,927 HALYS; using HALex
associated values, the model predicts that the
cohort suffered the loss of 265,184 HALYs (Table
2). For PUD, the predicted values for the US
population ranged from 597 HALYs lost when
scores associated with DALY measure were used
to 44,535 HALYs lost when scores associated with
the QWB scale were used; these variations were
attributable to the fact that the DALY score for
PUD was three hundredths of a decimal place
short of perfect health (Table 1).
The burden of disease ranking for COPD, dia-
betes, and asthma varied by measure, different
demographic group, or both. Although all mea-
sures estimated COPD as ranked highest in terms
of the overall burden of disease in the US popu-
lation cohort, the QWB scale predicted that this
disease would rank 2nd to diabetes mellitus
among black persons. Both the HALex measure
and the QWB scale estimated that diabetes mel-
litus would rank 2nd for the US population cohort
but 3rd among persons earning more than
$35,000. Using DALY scores, however, this disease
ranked 2nd for all groups. Burden of disease
estimates obtained using HRQL scores associated
with the YHL and QWB measure ranked asthma
as the 3rd leading cause of disability or death for
most demographically-defined groups whereas
HRQL scores associated with the DALY measure
assigned asthma the second lowest ranking for all
groups.
Discussion
The use of HRQL scores associated with
DALYs, QALYs, and YHLs produced discordant
HALY estimates for the five conditions examined.
More importantly, the absolute rank order of each
condition varied both by the measure used and the
demographic group under study.
Health-related quality of life scores typically
differ as a result of: (1) differences in the domains









YHL* 0.46 0.62 0.48 0.68 0.77
QWB* 0.68 0.69 0.67 0.67 0.68
DALY* 0.78 0.80 0.61 0.997 0.94
*YHL  HRQL scores associated with the years of healthy life measure,21 QWB  HRQL scores for the Quality
of Well-Being index derived from the Beaver Dam Study,20 DALY  HRQL scores associated with disability-
adjusted life-years for treated disease.3
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(attributes associated with a disease) that are
captured by the measures used;8,28 (2) disparate
methods used to generate the HRQL “weight” or
value (ie, time trade off, standard gamble, visual
analogue scale, person trade-off);10 (3) the way in
which comorbid illnesses are incorporated; and (4)
differences in the populations sampled. In assign-
ing values to HRQL, QALY-related measures such
as the QWB elicit preferences for disease-related
health states from a representative community
sample.8 Values for DALYs are obtained by asking
health professionals to judge the level of disability
associated with particular conditions, rather than
members of a representative community sample,
using person-trade-off exercises.3 The HALex cal-
culates HRQL weights using correspondence
analysis, a mathematical technique that maximizes
correlation between two domains of health (role
function and self perceived health) reported in a
nationally representative sample.4
There are a number of limitations to this study
that could affect the accuracy of the burden of
disease estimates we generated. First, disease-
specific mortality rates were unavailable by edu-
cation or by income. We therefore relied on all-
cause mortality rates for lower versus higher
income households, using data obtained from a
longitudinal mortality study.27 The five illnesses
presented may, in reality, exhibit different SES-
associated mortality patterns.
Second, in this study, consistent with the find-
ings of others that health status is affected by
socioeconomic status,29–32 loss of HALY by in-
come and race were greater in low-income per-
sons and black persons than in high-income per-
sons and white persons. The single exception to
this is for COPD, an illness that appears to be less
common in black persons.33 When race is consid-
ered, the YHL measure predicts a lower HRQL
score for black persons than for white persons.22
TABLE 2. Burden of Disease in Health-Adjusted Life-Years Lost Per 100,000 Persons for 5 Conditions
by Race, Family Income, and Health-Related Quality of Life (HRQL) Index
US Pop. $35,000 $10,000 White Black
Chronic obstructive pulmonary disease
YHL score* 265,184 (1) 225,121 (1) 321,489 (1) 280,249 (1) 185,834 (1)
QWB score* 169,927 (1) 143,585 (1) 206,412 (1) 179,534 (1) 119,283 (2)†
DALY score* 199,005 (1) 168,475 (1) 241,541 (1) 210,278 (1) 139,598 (1)
Diabetes mellitus
YHL score* 126,188 (2) 88,294 (3)† 194,562 (2) 117,297 (2) 179,115 (2)
QWB score* 117,297 (2) 72,302 (3)† 159,483 (2) 96,235 (2) 147,121 (1)
DALY score* 67,984 (2) 47,171 (2) 104,360 (2) 63,138 (2) 96,845 (2)
Asthma
YHL score* 102,928 (3) 92,067 (2)† 135,302 (3) 97,801 (3) 112,415 (3)
QWB score* 88,530 (3) 88,549 (2)† 112,085 (3) 88,458 (3) 100,946 (3)
DALY score* 28,884 (4)† 24,729 (4)† 37,622 (4)† 27,073 (4)† 33,827 (4)†
Stroke
YHL score* 80,302 (4) 62,928 (4) 105,849 (4) 77,584 (4) 91,168 (4)
QWB score* 49,602 (4) 38,189 (4) 65,248 (5)† 47,868 (4) 56,861 (4)
DALY score* 36,206 (3)† 27,394 (3)† 47,531 (3)† 34,902 (3)† 41,891 (3)†
Peptic ulcer
YHL score* 43,191 (5) 25,563 (5) 78,251 (5) 43,142 (5) 47,026 (5)
QWB score* 44,535 (5) 26,356 (5) 80,688 (4)† 44,484 (5) 48,488 (5)
DALY score* 597 (5) 434 (5) 980 (5) 599 (5) 666 (5)
*YHL  HRQL scores associated with the years of healthy life measure,21 QWB  HRQL scores for the Quality
of Well-Being index derived from the Beaver Dam Study,20 DALY  HRQL scores associated with disability-
adjusted life-years for treated disease.3
†Break in rank order of disease.
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Because only the HALex permits adjustment of
HRQL on the basis of sociodemographic descrip-
tors,22 we were unable to explore the impact of any
systematic differences between measure-
associated HRQL scores in the different sub-
populations studied. Because it was not possible to
incorporate these differences into our HRQL
scores, our estimates likely represent an underes-
timate of true disparities in HRQL between black
persons and whites.
Third, for some of the conditions, there were
insufficient subjects with which to assure reliable
age-specific prevalence rates in low income and
black persons. Finally, prevalence rates, which
were generated from self-reported survey data
from the National Health Interview Survey
(NHIS)25 may be subject to recall bias. Analyses by
the National Center for Health Statistics have
shown a  of 0.43 for overlap between medical
chart identified and self-reported conditions with
conditions requiring ongoing medical care such as
diabetes and hypertension having higher agree-
ment (  0.73 and 0.82, respectively),34 presum-
ably because patients are more likely to recall such
conditions. It is likely that recall bias is minimized
in symptomatic or severe conditions.
Although the limitations noted may influence
the accuracy of the burden of disease estimates
reported here, it is unlikely that the variation
between measures is affected given our use of the
same data sources for disease prevalence and life
tables for each measure. These differences are real,
and the problems they generate need scrutiny.
Burden of disease estimates have been taken into
account in prioritizing funding for public health
projects, and the rank order of conditions can
influence priorities for disease-specific research
investments.35 In addition, when QALYs are pri-
marily used for the evaluation of medical system
interventions and DALYs or YHLs for public
health interventions, opportunities for generating
meaningful comparisons between population-
based programs, and medical interventions vanish.
Canada has attempted to harmonize its ap-
proach to the evaluation of population health and
clinical medicine by using the Health Utility Index
in its National Population Health Survey. This
measure is used commonly in clinical settings, and
placement in a national survey allows clinical and
public health information to be collected in a
common HALY language which has been pro-
moted as a means for rationalizing health care
policy.36 The addition of the EuroQol (EQ-5D)
measure37 to the Agency for Health care Research
and Quality’s Medical Expenditures Panel Survey,
and the collection of US weights for the measure
are recent and welcome developments that will
provide a mechanism for developing one form of
QALY estimates for the US population. Given less
experience with the EQ-5D in clinical settings and
relative lack of familiarity to US researchers, it is
unclear, however, how extensively it will be used
in assessments of medical interventions.
Health-adjusted life years improve burden of
disease estimates and cost-effectiveness analyses
by allowing considerations of mortality and mor-
bidity in the same measures. Although variations
currently exist in the how life expectancy is esti-
mated for HALY measures, movement to a com-
mon approach would be relatively straightforward.
It is the debates about how to measure and value
health status that remain most open-ended. The
measures used in this paper represent a conve-
nience sample intended for illustrating that HRQL
variations will affect HALY estimates. This is a
limitation of the QALY methodology, which is well
reported within the clinical literature.38,39 Reach-
ing consensus on the best HRQL measure for
cost-effectiveness and burden of disease analysis
will require more side-by-side comparisons of
these instruments in representative populations to
understand how they perform across groups and
across illnesses and conditions. Also crucial to
advancement will be gaining a fuller understand-
ing of which measurement schema are most com-
prehensible, useful, and palatable to the decision
makers, clinicians and public health professionals
whose needs they were intended to fill.
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